Skip to main content
Signal8
Launch Terminal

Viridian Therapeutics, Inc.\DE (VRDN)

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

NASDAQ:VRDNHealthcare
-0.52%$24.67
AH$25.20+2.15%vs close
Mkt Cap$2.79B
Float97.43M
O/S113.29M
Vol
$ Vol
RVOL
Inst Own-
SI18.5%
Earnings
Dilution
Viridian Therapeutics, Inc. logoNASDAQ:VRDN$24.67-0.52%
Phase Distribution
15 lead-sponsored trials·3 active·9 completed
Phase 13
Phase 23
Phase 38
Phase 41
Status Overview
Not yet recruiting1
Active, not recruiting3
Completed9
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 4
    Not yet recruiting

    An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab

    veligrotrug (LUMVOA™)

    Thyroid Eye Disease

    Enrollment
    30
    Start
    Sep 2026est.
    Primary Completion
    Apr 2027est.
    Completion
    Sep 2027est.
    NCT07832136
  • Phase 3
    Completed

    A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

    Veligrotug, Placebo

    Thyroid Eye Disease

    Enrollment
    113
    Start
    Nov 2022
    Primary Completion
    Jul 2024
    Completion
    Mar 2025
    NCT05176639
  • Phase 3
    Completed

    An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

    Veligrotug, Placebo

    Thyroid Eye Disease

    Enrollment
    188
    Start
    Nov 2023
    Primary Completion
    Nov 2024
    Completion
    Jul 2025
    NCT06021054
  • Phase 3
    Completed

    An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

    Veligrotug

    Thyroid Eye Disease

    Enrollment
    139
    Start
    Jan 2024
    Primary Completion
    Apr 2025
    Completion
    Jun 2025
    NCT06179875
  • Phase 3
    Completed

    A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

    Veligrotug

    Thyroid Eye Disease

    Enrollment
    231
    Start
    May 2024
    Primary Completion
    May 2025
    Completion
    Jan 2026
    NCT06384547
  • Phase 3
    Active, not recruiting

    An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

    VRDN-003, Placebo

    Thyroid Eye Disease

    Enrollment
    204
    Start
    Aug 2024
    Primary Completion
    Mar 2026
    Completion
    Dec 2026est.
    NCT06625398
  • Phase 3
    Active, not recruiting

    An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

    VRDN-003, Placebo

    Thyroid Eye Disease

    Enrollment
    132
    Start
    Aug 2024
    Primary Completion
    Feb 2026
    Completion
    Nov 2026est.
    NCT06625411
  • Phase 3
    Active, not recruiting

    A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

    VRDN-003, Placebo

    Thyroid Eye Disease (TED)

    Enrollment
    320
    Start
    Feb 2025
    Primary Completion
    Apr 2026
    Completion
    Oct 2026est.
    NCT06812325
  • Phase 3
    Completed

    A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

    VRDN-003

    Thyroid Eye Disease

    Enrollment
    87
    Start
    Jul 2025
    Primary Completion
    May 2026
    Completion
    May 2026
    NCT07155668
  • Phase 2
    Completed

    Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

    Remlarsen, Placebo

    Keloid

    Enrollment
    14
    Start
    Jun 2018
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03601052
  • Phase 2
    Terminated

    SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

    Cobomarsen, Vorinostat

    Cutaneous T-Cell Lymphoma/Mycosis Fungoides

    Enrollment
    37
    Start
    Apr 2019
    Primary Completion
    Oct 2020
    Completion
    Dec 2020
    NCT03713320
  • Phase 2
    Terminated

    PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

    Cobomarsen

    Cutaneous T-Cell Lymphoma/Mycosis Fungoides

    Enrollment
    8
    Start
    Oct 2019
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT03837457
  • Phase 1
    Completed

    Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

    Cobomarsen

    Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) +3

    Enrollment
    66
    Start
    Feb 2016
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT02580552
  • Phase 1
    Completed

    Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

    MRG-201, Placebo

    Healthy Volunteers

    Enrollment
    54
    Start
    Nov 2015
    Primary Completion
    Apr 2017
    Completion
    Apr 2017
    NCT02603224
  • Phase 1
    Completed

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

    MRG-110, Placebo

    Healthy Volunteer

    Enrollment
    42
    Start
    Apr 2018
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT03603431
Search ClinicalTrials.gov for “Viridian Therapeutics”